ANI Pharmaceuticals Publishes NEW DAY Clinical Trial Results for ILUVIEN in Ophthalmology

The peer-reviewed study examines the use of ILUVIEN, a corticosteroid implant, for treating diabetic macular edema.

Apr. 7, 2026 at 11:00am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image of the internal structure of a human eye, with delicate lines and shapes glowing against a dark background, conceptually illustrating the medical research on a new therapy for a serious eye condition.The publication of clinical trial data on a novel treatment for diabetic macular edema sheds light on the complex inner workings of the eye.Princeton Today

ANI Pharmaceuticals, Inc. announced the publication of results from the NEW DAY clinical trial involving ILUVIEN (fluocinolone acetonide intravitreal implant), 0.19 mg, in the journal Ophthalmology. ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with corticosteroids. The company previously announced the trial results in July 2025.

Why it matters

The publication in Ophthalmology, a leading peer-reviewed ophthalmology journal, represents ANI's continued commitment to generating clinical data to support the use of ILUVIEN for patients living with DME, a serious complication of diabetes that can lead to vision loss.

The details

The NEW DAY trial evaluated the safety and efficacy of ILUVIEN, a sustained-release corticosteroid implant, in appropriate patients with DME. The published article is titled 'Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study'.

  • ANI previously announced the NEW DAY trial results in July 2025.
  • The published research article is currently available on the Ophthalmology website.

The players

ANI Pharmaceuticals, Inc.

A diversified biopharmaceutical company committed to developing, manufacturing, and commercializing innovative and high-quality therapeutics, with a focus on its Rare Disease, Generics, and Brands business segments.

ILUVIEN

A corticosteroid intravitreal implant indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Nikhil Lalwani

President and Chief Executive Officer of ANI Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“We are proud that the results from the NEW DAY clinical trial have been published in Ophthalmology, a leading, globally respected peer-reviewed journal. This publication represents our team's continued commitment to generating clinical data for patients living with DME and for the overall retina community.”

— Nikhil Lalwani, President and Chief Executive Officer of ANI Pharmaceuticals

The takeaway

The publication of the NEW DAY trial results in a prestigious ophthalmology journal underscores ANI's dedication to advancing treatment options and supporting the medical community in managing diabetic macular edema, a leading cause of vision loss among people with diabetes.